最新医学別冊  新しい診断と治療のABC8/免疫1 関節リウマチ 改訂第2版

出版社: 最新医学社
発行日: 2008-04-25
分野: 臨床医学:一般  >  雑誌
雑誌名:
特集: 関節リウマチ 改訂第2版
電子書籍版: 2008-04-25 (改訂第2版)
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

目次

  • 最新医学別冊 新しい診断と治療のABC8/免疫1 関節リウマチ 改訂第2版

    ―目次―

    特集 関節リウマチ 改訂第2版 

    序論

    第1章 概念・定義
     概念・定義
     疫学

    第2章 病理・病態生理
     病理-滑膜の炎症から骨破壊まで-
     病態生理-サイトカインの面から-
     病因

    第3章 関節外病変
     肺
     腎臓
     アミロイドーシス

    第4章 関節リウマチ類縁疾患
     悪性関節リウマチ
     若年性特発性関節炎
     成人Still病

    第5章 関節リウマチの診断
     診断
     検査
     画像所見
     鑑別診断
     活動性の評価と薬効判定

    第6章 管理・治療
     薬物療法・選択基準
     治療薬剤
     理学療法
     外科療法
     経過と予後
     医療経済

    第7章 関節リウマチ治療ガイドライン
     関節リウマチ治療ガイドライン
     生物学的製剤使用ガイドライン

    第8章 トピックス
     早期RA 長崎大学
     寛解の概念の変遷 Drug-free-emission
     Window of Opportunity
     生物学的製剤とニューモシスチス肺炎

    座談会 関節リウマチの治療の現状と展望

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 概念・定義, 疫学

P.16 掲載の参考文献
1) Rothschild B M, et al:Symmetrical erosive peripheral polyarthritis in the late archaic period of Alabama. Science 24:1498-1502, 1988.
2) Winchester R J:The molecular basis of susceptibility to rheumatoid arthritis. Adv Immunol 56:389-466, 1994.
3) Gregersen P K et al:The shared epitope hypothesis an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30:1205-1213, 1987.
5) 熊谷俊一:関節リウマチ診療の進歩-関節リウマチの臨床検査の進め方. 日医会誌 135(5):1043-1046, 2006.
7) van der Heidje D, et al:Radiographic progression on radiographs of hands and fee during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heidje modification). J Rheumatol 22:1792-1796, 1995.
9) van Doornum S, et al:Accelerated atherosclerosis. An extraarticular feature of rheumatoid arthrirtis? Arthritis Rheum 46:862-873, 2002.
10) Pincus T, et al:Taking mortality in rheumatoid arthritis seriously. Predictive markers, socioeconomic status and comorbidity. J Rheumatol 13:841-845, 1986.
P.24 掲載の参考文献
1) Silman A J, et al:Epidemiology of the rheumatic diseases. Oxford:Oxford University Press, 1993.
2) Felson D T, et al:Epidemiology of the rheumatic diseases. Arthritis and Allied Conditions (Koopman WJ, ed), 13th Ed, p3. Williams & Wilkins, Baltimore, 1996.
3) Arnett F C, et al:The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324, 1988.
4) 居村茂明:疫学と患者実態. 厚生省長期慢性疾患総合研究事業平成9年度研究報告書 p107. 1998.
5) Wood J W, et al:Rheumatoid arthritis in Hiroshima and Nagasaki, Japan prevalence, incidence, and clinical Characteristics. Arthritis Rheum 10:21-31, 1967.
6) 膳棟造, 他:慢性関節リウマチの疫学調査和歌山県白浜町. Clinical Rheumatol 1:354-359, 1988.
7) 古野純典:慢性関節リウマチの有病率と発症要因に関する疫学的研究. 平成10年度厚生科学研究費補助金免疫アレルギー等研究事業(免疫アレルギー部門)研究報告書. p200-202, 1999.
8) Wilder R L, et al:Rheumatoid arthritis:epidemiology, pathology, and pathogenesis. In:Primer on Rheumatic Diseases (Schumacher H R, eds), p86-89 Arthritis Foundation, Atlanta, 1993.
9) Dugowson C E, et al:Rheumatoid arthritis in women:incidence rate in group health cooperative, Seattle, Washington, 1978-1989. Arthritis Rheum 34:1502-1507, 1991.
10) Winchester R:The molecular basis of susceptibility to rheumatoid arthritis. Adv Immunol 56:389-466, 1994.
11) Weyand C M, et al:The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 117:801-806, 1992.
12) Winchester R, et al:The genetic basis of rheumatoid arthritis:the shared epitope hypothesis. Rheum dis Clin North Am 18:761-783, 1992.
13) Silman A J, et al:Twin concordance rates for rheumatoid arthritis:results from a nationwide study. Br J Rheum 32:903-907, 1993.
14) Pincus T, et al:Early mortality in RA predicted by poor clinical status. Bull Rheum Dis 41:1-4, 1992.
15) 山田昭夫:慢性間接リウマチの死因と生命予後に関係する因子について. 厚生省長期慢性疾患総合研究事業リウマチ調査研究総合研究報告書. p139-141, 1996.

第2章 病理・病態生理

P.41 掲載の参考文献
1) 澤井高志:関節炎の病理学. リウマチ学. p353-363. 同文書院, 東京, 1989.
2) 澤井高志:リウマチ性疾患の病理. 最新内科学体系免疫免疫/アレルギー性疾患, 慢性関節リウマチ (井村裕夫, 他 編), p89-107. 中山書店, 東京, 1993.
3) Robert I F, et al:Strucute and Function of Syoviocyte In:Arthritis and alied conditions (McCarty D J, et al, eds) pp263-278 Lea and Febiger, Philaderphia-London, 1993.
5) 澤井高志, 他:慢性関節リウマチ滑膜初期病変の免疫組織化学的検討-モノクロナル抗体を用いた炎症性細胞の定性ならびに定量的解析. リウマチ 30(4):247-254, 1990.
6) Sawai T, et al:In situ hybridization of stromelysin mRNA in the synovial biopsies from rheumatoid arthritis. Tohoku J Exp Med 178:315-330, 1996.
7) Schumacher H R Jr, et al:Histological appearance of the synovium in early rheumatoid arthritis. Sem Arthritis Rheum 23(6 Suppl 2):3-10, 1994.
8) Klareskog L, et al:Immune functions of human synovial cells. Phenotypic and T cell regulatory properties of macrophage-like cells that express HLA-DR. Arthritis Rheum 25(5):488-501, 1982.
9) Poulter L W, et al:Histochemical discrimination of HLA-DR positive cell populations in the normal and arthritic synovial lining. Clin Exp Immunol 48(2):381-388, 1982.
11) Takeuchi K, et al:Biochemical investigation of cell motile activity in rheumatoid synovial fluid. J Rheumatol 25(1):9-15, 1998.
12) Miller E J, et al:Interleukin-8:an important neutrophil chemotaxin in some cases of exudative pleural effusions. Exp Lung Res 19(5):589-601, 1993.
15) Yoshihara Y, et al:Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 59(6):455-461, 2000.
16) 宗像孝佳, 他:慢性関節リウマチにおける IL-18 の動態. リウマチ 41(3):625-634, 2001.
19) Zvaifier N J:Pannus and Pannocytes-Alternative models of jint destruction in rheumatoid arthritis. Arthrits Rheum 37(6):783-789, 1994.
20) 井上尚美, 他:慢性関節リウマチ (RA) 関節破壊に関与する酸性プロテアーゼ (カテプシンD) の活性化機構に関する免疫組織化学的解析. 炎症 15(4) 505-507, 1995.
21) 田中真希, 他:MRL/Mp-1pr (MRL/1) マウス関節病変における軟骨, 骨組織の変化 (第1報)-ossification groove of Ranvier の関節破壊の場としての意義-. 炎症 17(2):129-134, 1997.
30) Yatsugi N, et al:Apoptosis of articular chondrocytes in rheumatoid arthritis and osteoarthritis:correlation of apoptosis with degree of cartilage destruction and expression of apoptosis-related proteins of p53 and c-myc. J Orthop Sci 5(2):150-156, 2000.
31) 長田重一:加熱しているアポトーシス研究. 実験医 17(13):1598-1602, 1999.
32) Uzuki M, et al:Apoptotic chondrocyte and matrx metalloproteinases in rheumatoid arthiritis. Arthritis Rheum 43(suppl):1915, 2000.
33) Seki M, et al:Matrix metalloproteinas 9(MMP-9) inn patients with rheumatoid arthritis. Jap J Rheumatol 7(3):197-209, 1997.
34) 伊藤 崇, 他:慢性関節リウマチ血清, 関節液中の Metalloproteinase (MMP-13) の動態.-血清, 関節液の濃度, 活性化と関節組織での蛋白, mRNA の発現-. リウマチ 42(1):60-69, 2002.
36) Kotake S, et al:IL-17 in synovial fluids from patients with rheumatoid arthritis is apotent stimulator of osteoclastogenesis. J Clin Invest 103(9):1345-1352, 1999.
37) Cronstein B N:Interleukin-6-a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis 65(Suppl 1):S11-15, 2007.
38) Nakahara H, et al:Anti-interleukin-6 receptor antibody therapy in rheumatic diseases. Endocr Metab Immune Disord Drug Targets 6(4):373-381, 2006.
39) Feldmann M, et al:Anti-TNF alpha therapy of rheumatoid arthritis:what have we learned? Ann Rev Immunol 19:163-196, 2001.
40) Charles P, et al:Regulation of cytokines, cytokine inhibitors, and acute phase proteins of following and anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163(3):1521-1528, 1999.
P.56 掲載の参考文献
2) Arend W P, et al:Cytokine networks. In:Rheumatoid arthritis:frontiers in pathogenesis and treatment, second edition (Firestein G S, et al, eds). p173-192. Oxford University Press, Oxford, 2006.
3) Firestein G S, et al:Invasive fibroblast-like synoviocytes in rheumatoid arthritis, Passive responders or transformed aggressors? Arthritis Rheum 39(11):1781-1790, 1996.
6) Paleolog E M:Angiogenesis in rheumatoid arthritis. Arthritis Res 4(Suppl 3):S81-90, 2002.
7) Park C C, et al:Evidence of IL-18 as a novel angiogenic mediator. J Immunol 167(3):1644-1653, 2001.
9) Blaschke S, et al:Proinflammatory role in fractalkine (CXCL1) in rheumatoid arthritis. J Rheumatol 30(9):1918-1927, 2003.
10) McInnes I B, et al:The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 2(2):175-182, 1996.
12) Nanki T, et al:Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol 165(11):6590-6598, 2000.
13) Bannou F, et al:Cartilage breakdown in rheumatoid arthritis. Joint Bone Spine 73(1):29-36, 2006.
14) Goldring S R, et al:Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 12(3):200-204, 2000.
15) Takayanagi H, et al:Involvement of receptor activator of nuclear factor κB ligand/osteoblast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43(2):259-269, 2000.
16) Kobayashi K, et al:Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191(2):275-286, 2000.
17) Jimi E, et al:Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res 247(1):8493, 1999.
21) Paz K, et al:A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 272(47):29911-299118, 1997.
22) Evangelos T H, et al:Role of cyotokines. In:Rheumatoid arthritis (St Clair E W, et al, eds), p134-149. Lippincott Williams & Wilkins, Philadelphia, 2004.
23) Karin M, et al:Phosphorylation meets ubiquitination:the control of NF-κB activity. Annu Rev Immunol 18:621-663, 2000.
26) Handel M L, et al:Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 38(12):1762-1770, 1996.
27) Cope A P, et al:The central role of T cells in rheumatoid arthritis. Clin Exp Rheumatol 25(5 Suppl 46):S4-11, 2007.
28) Firestein G S, et al:How important are T cells in chronic rheumatoid synovitis?:II. T cell-independent mechanisms from beginning to end. Arthritis Rheum 46(2):298-308, 2002.
29) McInnes I B, et al:Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis. Nat Med 3(2):189-195, 1997.
31) Qin S, et al:The chemokine receptors CX-CR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 101(4):746-754, 1998.
32) Morita Y, et al:Flow cytometric single-cell analysis of cytokine production by CD4+ T cells in synovial tissue and peripheral blood from patients with rheumatoid arthritis. Arthritis Rheum 41(9):1669-1676, 1988.
33) Aarvak T, et al:IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 162(3):1246-1251, 1999.
34) Chabaud M, et al:Human interleukin-17:a T cell-derived proinflammatory cytokine produced by the rheumatoid synoivum. Arthritis Rheum 42(5):963-970, 1999.
37) Yamamura M, et al:Interferon-y-inducing activity of interleukin-18 in the joint of rheumatoid arthritis. Arthritis Rheum 44(2):275-285, 2001.
38) Aita T, et al:Expression of interleukin 12 receptor (IL-12R) and IL-18R on CD4+ T cells from patients with rheumatoid arthritis. J Rheumatol 31(3):448-456, 2004.
39) Jovanovic D V, et al:IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1β and TNF-a, by human macrophages. J Immunol 160(7):3513-3521, 1998.
40) Chabaud M, et al:Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 161(1):409-414, 1998.
44) Koenders M I, et al:Potential new targets in arthritis therapy:interleukin (IL)-17 and its relation to tumor necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 65(Suppl III):iii29-iii33, 2006.
45) Acosta-Rodriguez E V, et al:Interleukin 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8(9):942-949, 2007.
47) Yamada H. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann Rheum Dis (Epub ahead of print).
48) Miossec P:Intereleukin-17 in fashion, at last. Ten years after its description, its cellular source has been identified. Arthritis Rheum 56(7):2111-2115, 2007.
P.66 掲載の参考文献

第3章 関節外病変肺

P.76 掲載の参考文献
1) Fewins H E, et al:High definition computed tomography in rheumatoid arthritis associated pulmonary disease. Br J Rheumatol 30(3):214-216, 1991.
2) Anaya J M, et al:Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum 24(4):242-254, 1995.
3) Wolfe F:The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol 27(3):630-637, 2000.
4) Cortet B, et al:Pulmonary function tests and high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 56:596-600, 1997.
5) Despaux J, et al:Prospective study of the prevalence of bronchiectasis in rheumatoid arthritis using high-resolution computed tomography. Rev Rhum Engl Ed 65(7-9):453-461, 1998.
8) 河端美則:特発性間質性肺炎1-病理像と亜分類. 治療学 36(6);561-564, 2002.
9) 大石尚史, 他:慢性関節リウマチの肺病変の病理と臨床像. 臨床リウマチ 11(4):269-274, 1999.
10) Liebow A A, et al:Definition and classification of interstitial pneumonias in human pathology. Prog Respir Res 8:1-31, 1975.
12) American Thoracic Society. Idiopathic pulmonary fibrosis:diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161(2 Pt 1):646-664, 2000.
13) 近藤康博, 他:外科的生検肺の組織学的分類に基づく膠原病随伴間質性肺疾患の臨床的特徴と予後. 日呼吸会誌 38(4):259-266, 2000.
15) Dawson J K, et al:Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonaryfunction tests. Thorax 56(8):622-627, 2001.
16) Rajasekaran B A, et al:Interstitial lung disease in patients with rheumatoid arthritis:a comparison with cryptogenic fibrosing alveolitis. Rheumatology (Oxford) 40(9):1022-1025, 2001.
18) Dawson J K, et al:Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis Ann Rheum Dis 61(6):517-521, 2002.
19) Mack U, et al:Fatal diffuse alveolar damage after gold medication. Pneumologie 48(5):405-408, 1994.
20) Zisman D A, et al:Drug-induced pneumonitis:the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis 18(3):243-252, 2001.
21) Ogawa D, et al:Successful use of cyclosporin A for the treatment of acute interstitial pneumonitis associated with rheumatoid arthritis. Rheumatology (Oxford) 39(12):1422-1424, 2000.
22) Salomaa E R, et al:Complement components and their activation products in pleural fluid. Chest 114(3):723-730, 1998.
23) Inokuma S, et al:Bucillamine induced pulmonary injury occurs with immunoglobulin decrease. J Rheumatol 23(7):1282-1285, 1996.
P.83 掲載の参考文献
1) Nakano M, et al:Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol 50(3):154-160, 1998.
2) Helin H J, et al:Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum 38(2):242-247, 1995.
3) Saito T, et al:An ultrastructural study of glomerular basement membrane in rheumatoid arthritis patients with urinary abnormalities. Clin Nephrol 43(6):360-367, 1995.
6) Nakano M, et al:Determination of IgA-and IgM-rheumatoid factors in patients with rheumatoid arthritis with and without nephropathy. Ann Rheum Dis 55(8):520-524, 1996.
7) Korpela M, et al:Mesangial glomerulonephritis as an extra-articular manifestation of rheumatoid arthritis. Br J Rheumatol 36(11):1189-1195, 1997.
8) Hall C L, et al:The natural course of gold nephropathy:long term study of 21 patients. Br Med J 295(6601):745-748, 1987.
9) Hall C L, et al:Natural course of penicillamine nephropathy:a long term study of 33 patients. Br Med J 296(6629):1083-1086, 1988.
10) 中野正明:関節リウマチの腎障害に対する留意点. 日内会誌94(5):859-863, 2005.
11) 中野正明:抗リウマチ薬による腎障害. 腎と透析 47(3):365-369, 1999.
12) Mangge H, et al:Cystatin C, an early indicator for incipient renal disease in rheumatoid arthritis. Clin Chim Acta 300(1-2):195-200, 2000.
13) 中野正明, 他:新しい腎機能評価法としてのシスタチンCの RA における有用性. リウマチ科 36(3):305-311, 2006.
14) Ito S, et al:Renal stones in patients with rheumatoid arthritis. J Rheumatol 24(11):2123-2128, 1997.
P.91 掲載の参考文献
1) 稲田進一:慢性関節リウマチと二次性アミロイドーシス. リウマチ 40(5):849-856, 2000.
3) 豊島元, 他:剖検輯報からみた慢性関節リウマチの死因-とくにアミロイドーシスとの関連から-. リウマチ 33(3):209-214, 1993.
4) Tiitinen S, et al:Amyloidosis:incidence and early risk factors in patients with rheumatoid arthritis. Scand J Rheumatol 22:158-161, 1993.
5) 奥田恭章, 他:アミロイドーシスの診療. リウマチ科 27(suppl 1):933-938, 2002.
6) 奥田恭章, 他:アミロイドーシス合併 RA の早期診断と予後. リウマチ科 21(5):460-465, 1999.
7) 松田剛正:消化管アミロイドーシス. リウマチ科 21(5):446-450, 1999.
8) Korpela M, et al:Isolated microscopic hematuria in patients with rheumatoid arthritis compared with age and sex matched controls. A population based study. J Rheumatol 22:427-431, 1995.
9) Helin H J, et al:Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum 38:242-247, 1995.
10) 中野正明, 他, RA アミロイドーシスの腎障害. リウマチ科 21(5):451-459, 1999.
11) 中村正, 他:慢性および悪性関節リウマチの死因に関する臨床的研究. リウマチ 41(4):736-744, 2001.
12) 奥田恭章, 他:慢性関節リウマチに合併した 2次性アミロイドーシス124例の臨床的検討-胃一二指腸生検による診断と予後を中心として-. リウマチ 34(6):939-946, 1994
13) 安田正之:「MTX療法」におけるMTX選択基準に関して. 日本臨床リウマチ学会誌 13(9):174-181, 2001.
14) 安田正之, 他:慢性関節リウマチ患者におけるメトトレキセートによる骨髄障害.-国内外の報告の総覧-. 医療 55(7):311-321, 2001.
17) Elkayam O, et al:Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 46:2571-2573, 2002.
18) Ueda M, et al:FK506 inhibits murine AA amyloidosis:possible involvement of T cells in amyloidogenesis. J Rheumatol 33:2260-2270, 2006.
19) 海津嘉蔵,他:ネフローゼ症候群と抗血小板療法日内会誌 86:1639-1643, 1997.
20) Crofford L J:Specific cyclooxygenase-2 inhibitors:what have we learned since they came into widespread clinical use? Curr Opin Rheumatol 13:225-230, 2002.
21) Ylinen K, et al:Outcome of patients with secondary amyloidosis in dialysis treatment Nephrol Dial Transplant 7:908-912, 1992.

第4章 類縁疾患

P.101 掲載の参考文献
1) Bevans M, et al:The systemic lesions of malignant rheumatoid arthritis. Am J Med 16:197-211, 1954.
2) 厚生省特定疾患悪性関節リウマチ 結節性動脈周囲炎研究班 (班長塩川優一):悪性関節リウマチの診断の手引き 1973年度研究報告書 p4-5. 1974.
3) 橋本博史, 他:悪性関節リウマチの改定診断基準と治療指針 (案). 厚生省特定疾患系統的脈管障害調査研究班 1987年度研究報告書 p189-191. 1988.
4) 京極方久, 他:悪性関節リウマチの病理組織学的特徴. リウマチ 15:483-487, 1975.
5) Watts R A, et al:The incidence of rheumatoid vasculitis in the Norwich Health Authority. Br J Rheumatol 33:832-833, 1994.
7) 橋本博史, 他:悪性関節リウマチ小委員会報告厚生省特定疾患系統的脈管障害調査研究班 1986年度研究報告書, p33. 1987.
8) Puechal X, et al:Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. A clinicopathologic and prognostic study of thirty-two patients. Arthritis Rheum 38:1618-1629, 1995.
9) Voskuyl A E, et al:Factors associated with the development of vasculitis in rheumatoid arthritis:results of a case-control study. Ann Rheum Dis 55:190-192, 1996.
10) Geirsson A J, et al:Clinical and serological features of severe vasculitis in rheumatoid arthritis:prognostic implications. Ann Rheum Dis 46:727-733, 1987.
11) 中野正明, 他:抗 CCP 抗体測定の疾患活動性の指標としての有用性の検討. 第48回リウマチ学会 284, 2004.
12) 中村正, 他:慢性および悪性関節リウマチの死因に関する臨床的研究. リウマチ 41:736-744, 2001.
14) 織部元廣, 他:吸着法か膜分離法か悪性関節リウマチの難治病態治療における免疫吸着療法と二重膜ろ過血漿交換療法の比較検討. 医工治療 16(supp):68, 2004.
15) Scott D G, et al:Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 76:377-384, 1984.
16) 宮正彦:悪性関節リウマチに対するタクロリムスの使用経験. 国際リウマチシンポジウムプログラム 16:419, 2007.
17) Unger L, et al:Successful treastment of severe rheumatoid vasculitis by infliximab. Ann Rheum Dis 62:587-588, 2003.
18) Puechal X, et al:Anti-Tumor Necrosis Factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis, Ann Rheum Dis nov epub 2007. Genta M S, et al:Systemic rheumatoid vasculitis:a review. Semin Arthritis Rheum 36:88-98, 2006.
21) Stokes M B:Development of glomerulonephritis during anti-TNFα therapy for rheumatoid arthritis. Nephrol Dial Transplant 20:1400-1406, 2005.
22) 高林克日己, 他:自己免疫疾患患者にみられる日和見感染症の検討. 日内会誌 78:1294-1298, 1989.
23) 熊谷俊一:中大量ステロイド投与膠原病患者におけるステロイド骨粗鬆症の前向きコホート多施設研究免疫疾患の既存治療法の評価とその合併症に関する研究班報告. 2007.
P.112 掲載の参考文献
1) Harrington J, et al:Developmental issues in adolescence and the impact of rheumatic disease. In:Adolescent Rheumatology (Isenberg D A, et al, eds), p21-34. Martin Dunitz, London, 2000.
2) Fink C W:Proposal for the development of classification criteria for idiopathic arthritides of childhood, J Rheumatol 22:1566-1569, 1995.
3) 横田俊平:小児慢性関節炎の最近の治療法の進歩. リウマチ 39:860-866, 2000.
4) Rooney M, et al:Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 34:454-460, 1995.
5) Clutterbuck R, et al:Interleukin-6 and other gp130-dependent cytokines selectively inhibit proliferation of macrophage-lineage hemopoietic progenitor cell. Exp Hematol 28:1120-1128, 2000.
6) Yokota S, et al:Therapeutic efficacy of humanized anti-IL6-receptor antibody in systemic juvenile idiopathic arthritis (abstract). The 2001 65th Annual Scientific Meeting of the American College of Rheumatology.
7) Stephan J L, et al:Macrophage activation syndrome and reumatic disease in chidhood a report of four new cases. Clin Exp Rheumatol 11:451-456, 1993.
8) 今川智之, 他:マクロファージ活性化症候群:高サイトカイン血症とその病態. Mol Med 33:1052-1060, 1996.
9) 横田俊平:若年性関節リウマチとぶどう膜炎. リウマチ 34:790-794, 1994.
10) 横田俊平, 他:若年性関節リウマチに対する DMARDs 治療法の新展開~-メトトレキサートを中心とするMAP療法の試み. 小児科 36:271-281, 1995.
P.120 掲載の参考文献
1) Valtonen J M O, et al:Serological findings in patients with acute syndromes fulfilling the proposed criteria of adult onset Still's disease. Scand J Rheumatol 26:342-345, 1997.
2) Sugiura T, et al:Association between adult-onset Still's disease and interleukin-18 gene polymorphisms. Genes Immun 3:394-399, 2002.
3) Hwang S Y, et al:Allelic frequency of the MCP-1 promotor-2518 polymorphism in the Korean population and in Korean patients with rheumatoid arthritis, systemic lupus erythematosus and adult-onset Stil's disease. Eur J Immunogenet 29:413-416, 2002.
4) Sugiura T, et al:A promotor haplotype of the interleukin-18 gene is associated with juvenile idiopathic arthritis in the Japanese population. Arthritis Res Ther 8:R60.
5) Fishman D, et al:The effect of novel polymorphysm in the interleukin-6(IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369-1376, 1998.
6) Hoshino T, et al:Elevated serum IL-6, IFN-γ and TNF-α levels in patients with adult Still's disease. J Rheumatol 25:396-398, 1998.
7) Kawashima M, et al:Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 44:550-560, 2001.
9) Wakai K, et al:Estimated prevalence and incidence of adult Still's disease:findings by a nationwide epidemiological survey in Japan. J Epidemiol 7:221-225, 1997.
10) Ohta A, et al:Adult Still's disease:a multicenter survey of Japanese patients. J Rheumatol 17:1058-1063, 1990.
11) Pouchot J, et al:Adult Still's disease:manifestations, disease course, and outcome in 62 patients. Medicine 70:118-136, 1991.
12) Wouters J M G W, et al:Adult-onset Still's disease; clinical and laboratory features, treatment and progress of 45 cases. Quart J Med 61:1055-1063, 1986.
13) 山口雅也, 他:成人スチル病にみられる皮疹. 医事新報 3469:37-40, 1990.
14) Stephan J L, et al:Macrophage activation syndrome and rheumatic disease in childhood:a report of four new cases Clin Exp Rheumatol 11:451-456, 1993.
15) Yamaguchi M, et al:Preliminary criteria for classification of adult Still's disease. J Rheumatol 19:424-430, 1992.
16) Fujii T, et al:Methotrexate treatment in patients with adult onset Still's disease-retrospective study of 13 Japanese cases Ann Rheum Dis 56:144-148, 1997.
17) Marchesoni A, et al:Cyclosporin A in the treatment of adult-onset Still's disease. J Rheumatol 24:1582-1587, 1997.
18) 大田明英, 他:成人Still 病の治療と経過-全国調査集計より-, 厚生省特定疾患自己免疫疾患調査研究班平成7年度研究報告書, p.163-165. 1996.
19) Efthimiou P, et al:Adult-onset Still's disease:can recent advances in our understanding of its pathogenesis lead to targeted therapy? Nat Clin Pract Rheumatol 3:328-335, 2007.
20) Fautrel B, et al:Tumor necrosis factor alpha blocking agents in refractory adult Still's disease:an observational study of 20 cases. Ann Rheum Dis 64:262-265, 2005.
21) Prahalad S, et al:Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 28:2120-2124, 2001.

第5章 診断

P.126 掲載の参考文献
1) American College of Rheumatology Sub-committee on Rheumatoid arthritis guidelines:Guidelines for the management of rheumatoid arthritis. 2002 update. Arthritis Rheum 46:328-346, 2002.
2) Lipsky P E:Rheumatoid arthritis. In:Harrison's Principles of Internal Medicine, 16th edition, (Kasper D L, et al, eds) pp1968-1977. McGraw-Hill, Columbus, 2005.
3) Arnett F C, et al:The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324, 1988.
4) Scott D L:The diagnosis and prognosis of early arthritis:rationale for new prognostic criteria Arthritis Rheum 46:286-290, 2002.
5) 近藤啓文, 他:日本リウマチ学会による早期慢性関節リウマチの早期診断. 3. 診断基準の検証. リウマチ 40:54-59, 2000.
7) http://www.das-score.nl/
8) van der Heijde D M:Plain X-rays in rheumatoid arthritis:overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 10:435-453, 1996.
P.141 掲載の参考文献
2) Arnett F C, et al:The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324, 1988.
4) American College of Rheumatology Subcomittee on Rheumatoid Arthritis Guidelines:Guidelines for the management of rheumatoid arhthritis. 2002 update. Arthritis Rheum 44:1496-1503, 2001.
5) Prevoo M L, et al:Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-48, 1995.
7) Miyasaka N, et al:Guidelines fbr the proper use of etanercept in Japan. Mod Rheumatol 16:63-67, 2006.
8) Koike R, et al:Update on the Japanese guidelines fbr the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 17:451-458, 2007.
11) van Leeuwen M A, et al:Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 24:20-27, 1997.
12) Emery P:Rheumatoid arthritis:not yet curable with early intensive therapy. Lancet 350:304-305, 1997.
14) Nell V P K, et al:Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 64:1731-1736, 2005.
15) Boers M, et al:Infiammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis. Arthritis Rheum 44:2242-2246, 2001.
16) Papadopoulos I A, et al:Clinical course and outcome of early rheumatoid arthritis. Rheumatol Int 20:205-210, 2001.
17) Jansen L M, et al:Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 60:924-927, 2001.
20) Tamai M, et al:Bone edema determined by magnetic resonance imaging reflects severe disease status in patients with earlystage rheumatoid arthritis. J Rheumatol 34:2154-2157, 2007.
P.153 掲載の参考文献
1) 高岸憲二:滑膜切除の方法.臨床整形外科手術全書, p.136. 金原出版, 東京, 1994.
2) 松井宣夫, 他:慢性関節リウマチの画像診断. リウマチ 34:993, 1994.
6) 工藤興亮,他:三次元画像の基礎と応用. 整形災害外科 40:1227-1233, 1997.
7) Burk D L, et al:Recent advances in magnetic resonance imaging of the knee. Radiol Clin North Am 28:378-393, 1990.
8) 西岡英次:【外来診療に必要な超音波診断マニュアル】RA の超音波による画像診断 Orthopaedics 19(11):110-114, 2006.
10) Shulte M, et al:Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 40:1637-1643, 1999.
P.169 掲載の参考文献
1) Van Riel P L C M, et al:Clinical assessments in rheumatoid arthritis. In:Therapy of systemic rheumatic disorders (van de Putte L B A, et al, eds), p31-43. Marcel Dekker, Inc, New York, 1998.
2) Felson D T, et al:The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 36:729-740, 1993.
3) Prevoo M L, et al:Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-48, 1995.
4) 近藤啓文:慢性関節リウマチの活動性判定 (ACRコアセットなど). リウマチ 37:825-831, 1997.
5) Lansbury J:Report of a three-year study on the systemic and articular indexes in rheumatoid arthritis. Arthritis Rheum 1:505-522, 1958.
6) Tugwell P, et al:A methodologic framework for developing and selecting endo-points in clinical trials. J Rheumatol 9:758-762, 1982.
7) OMERACT Conference on outcome measures in rheumatoid arthritis clinical trials. J Rheumatol 20:525-591, 1993.
8) American College of Rheumatology Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials:Reduced joint counts in rheumatoid arthritis clinical trials. Arthritis Rheum 37:463-464, 1994.
9) Felson D T, et al:American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727-735, 1995.
11) Roberts R S:Pooled outcome measures in arthritis:the pros and cons. J Rheumatol 20:566-567, 1993.
12) Van der Heijde D M F M, et al:Validity of single variables and indices to measure disease activity in rheumatoid arthritis. J Rheumatol 20:538-541, 1993.
13) van Gestel A M, et al:Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and World Helth Organization/lnternational League Against Rheumatism Criteria. Arthritis Rheum 39:34-40, 1996.
14) Sato H, et al:Validity and reliability of a revised Japanease version of the Arthritis impact Measurement Scales versions (AIMS2). Mod Rheumatol 10:247-255, 2000.

第6章 管理・治療

P.175 掲載の参考文献
1) 柏崎禎夫, 他:慢性関節リウマチの今日の治療戦略. リウマチ 36(5):713-802, 1996.
2) Wilske K, et al:Remodeling the pyramid; a concept whose time has come. J Rheumatol 16:565-567, 1989.
3) American College of Rheumatology Sub-committee on Rheumatoid Arthritis Guidelines:Guidelines for the management of rheumatoid arthritis:2002 Update. Arthritis Rheum 46(2):328-346, 2002.
4) Felson D T, et al:American college of rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727-735, 1995.
5) Prevoo M L, et al:Modified disease activity scores that inlclude twenty-eight-joint counts Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44-48, 1995.
P.183 掲載の参考文献
1) Vane J R:Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231(25):232-235, 1971.
2) Kawai S, et al:Recent advances in nonsteroidal anti-inflammatory drugs. Allergol Int 54(2):209-215, 2005.
3) Kawai S:Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs:a clinical consideration. Inflamm Res 47(Suppl 2):S102-106, 1998.
4) Kojima F, et al:Coexpression of microsomal prostaglandin E synthase with cyclooxygenase-2 in human rheumatoid synovial cells. J Rheumatol 29(9):1836-1842, 2002.
5) 川合眞一:10非ステロイド抗炎症薬, 鎮痛解熱薬, 総合感冒薬. 今日の治療薬2007(水島裕編), p.256-264. 南江堂, 東京, 2007.
7) Chang D M, et al:Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis. Clin Rheumatol 20(2):104-113, 2001.
8) Silverstein F E, et al:Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis:the CLASS study:A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284(10):1247-1255, 2000.
10) Bjorkman D J:Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States:risk factors and frequency of complications. Am J Med 107(6A):3S-8S, 1999.
13) Chan F K, et al:Combination of a cyclooxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk:a double-blind, randomised trial. Lancet 369(9573):1621-1626, 2007.
14) Bombardier C, et al:VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343(21):1520-1528, 2000.
15) Bresalier R S, et al:Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352(11):1092-1102, 2005.
16) Solomon S D, et al:Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071-1080, 2005.
20) 川合 眞一:妊娠, 出産における薬物療法の注意点. リウマチ科 26(1):35-38, 2001.
23) Yamazaki R, et al:Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J pharmacol Exp Ther 302(1):18-25, 2002.
P.192 掲載の参考文献
1) Taniguchi A, et al:Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis:a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet Genomics 17(6):383-390, 2007.
2) Tsujimura S, et al:Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis 2007(Epub ahead of prinrt)
3) Weinblatt M E, et al:Methotrexate in rheumatoid arthritis:effects on disease activity in a multicenter prospective study. J Rheumatol 18:334-338, 1991.
4) Lopez-Mendez A, et al:Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two. Arthritis Rheum 36:1364-1369, 1993.
5) Yamanaka H, et al:Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol 17(4):283-289, 2007.
6) Yamanaka H, et al:Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients:evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). Mod Rheumatol 17(2):98-105, 2007.
7) Ortiz Z, et al:The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 25:36-43, 1998.
8) Smolen J S, et al:Efficacy and safety of leflunomide compared with placebo and sulphasarazine in active rheumatoid arthritis:a double blind, randomized, multicentre trial. Lancet 353:259-266, 1999.
9) Yasuda M, et al:Efficacy of additive DMARD therapy in patients with rheumatoid arthritis. Double blind controlled trial using bucillamine and placebo with maintenance doses of gold sodium thiomalate. J Rheumatol 21:44-50, 1994.
10) Iwatani M, et al:Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. Mod Rheumatol 16(6):376-380, 2006.
12) Emery P, et al:Acomparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 39:655-665, 2000.
13) Hirabayashi Y, et al:Leflunomide-induced pneumonitis in a patient with rheumatoid arthtritis. Intern Med 45(10):689-691, 2006.
15) Ichikawa Y, et al:Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis:a multicenter, double-blind, randomized controlled study. Modern Rheumatol 15(5) 323-328, 2005.
17) American College of Rheumatology Subcomittee on rheumatoid arthritis guidelines:Guideline for the management ofrheumatoid arthritis. 2002 update. Arthritis Rheum 46:328-346, 2002.
18) Pinals R S, et al:Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24:1308-1315, 1981.
19) Tanaka E, et al:Efficient management of Rheumatoid Arthritis significantly reduces long-term functional disability. Ann Rheum Dis. 2007(Epub ahead of print)
P.203 掲載の参考文献
1) Hench P S, et al:The effect of a hormone of the adrenal cortex (17-hydroxy-11-deoxy-corticosterone:compaound E) and of the pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 24:181, 1949.
4) 鈴木康夫, 他:ステロイドの消炎鎮痛作用と副作用. 痛みと臨 1:224-230, 2001.
5) Pincus T, et al:Are long-term very low dose of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful? Ann Intern Med 136:76-78, 2002.
6) 鈴木康夫, 他:慢性関節リウマチ-最近の動向-ステロイド剤.診と治 76:307-310, 1988.
7) Harris E D, et al:Low dose prednisolone therapy in rheumatoid arthritis. A double blind study. J Rheumatol 10:713-721, 1983.
8) Hickling P, et al:Joint destuction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low-dose Glucocorticoid Study Group. Br J Rheumatol 37:930-936, 1998.
9) van Everdingen A A, et al:Low-dose prednisone therapy for patients with early active rheumatoid arthritis:Clinical efficacy, disease-modifying properties, and Side effects. A randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136:1-12, 2002.
10) Svensson B, et al:Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate. A two-year randomized trial. Arthristis Rheum 52:3360-3370, 2005.
11) Wassenberg S, et al:Very low-dose prednisolone in early rheumatoid arthritis reatards radiographic progression over two years. A multicenter, double-blind, placebo controlled trial. Arthritis Rheum 52:2271-2280, 2005.
14) Ichikawa Y, et al:ECG abnormalities in steroid-treated rheumatoid arthritis. Lancet 2:828, 1977.
16) 鈴木康夫, 他:慢性関節リウマチにおける骨病変 日臨 60(suppl 3):407-417, 2002.
17) Goekoop-Ruiterman Y P M, et al:Comparison of treatment strategies in early rheumatoid arthritis. A randomized trial. Ann Intern Med 146:406-415, 2007.
P.215 掲載の参考文献
3) Maini R N, et al:Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50:1051-1065, 2004.
4) Lipsky PE, et al:Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594-1602, 2000.
5) Keane J, et al:Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Eng J Med 345:1098-1104, 2001.
6) Takeuchi T, et al:Postmarketing surveillance of the safety profile of infliximab in 5,000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67:189-194, 2008.
12) Breedveld F C, et al:The PREMIER study:A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26-37, 2006.
15) Nishimoto N, et al:Study of Active Controlled Monotherapy Used for Rheumatoid Arthritis, an IL-6 inhibitor (SAMURAI):Evidence of clinical and radiographic benefit from an X-Ray Reader-Blinded Randomized Controlled Trial of Tocilizumab. Ann Rheum Dis 66:1162-1167, 2007.
16) Lundquist L:Abatacept:a novel therapy approved for the treatment of patients with rheumatoid arthritis. N Engl J Med 24:333-345, 2007.
17) Genovese M C, et al:Abatacept fbr rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 353:1114-1123, 2005.
P.224 掲載の参考文献
1) WHO:International classification of impairments, activities, and participation (ICIDH-2). World Health Organization, Geneva, 1998.
2) 橋本明:慢性関節リウマチのプールによるリハビリテーションの実際. リウマチ科 10:365-376, 1993.
P.233 掲載の参考文献
1) Adams W, et al:Arthrodesis of the hind foot in rheumatoid arthritis. Ortho Clin N Ame 7:827-840, 1976.
2) Dearborn J T, et al:High replacement of an acetabular component inserted without cement in a revision total hip arthroplasty. Result after a mean of ten years. J Bone Joint Surg 81A:469-480, 1999.
3) Engh G A, et al:A midvastus muscle splitting approach for total knee arthroplasty. J Arthroplasty 12:322-331, 1997.
5) Hanyu T, et al:Survivorship analysis of total knee arthroplasty with the kinematic prosthesis in patients who have rheumatoid arthritis. J Arthroplasty 12:913-919, 1997.
6) 北爪伸仁, 他:髄内釘ねじ横止め法による足関節固定法について, 骨折9:33-38, 1987.
7) Laskin R S, et al:Total knee replacement with posterior cruciate ligament retention in rheumatoid arthritis. Problems and complications. Clin Orthop 345:24-28, 1997.
8) 犀川勲, 他:Fin付き髄内釘を用いた足関節固定術の経験整形外科 51:855-859, 2000.
9) Schai P A, et al:Total knee arthroplasty with posterior cruciate retention in patients with rheumatoid arthritis. Clin Orthop 367:96-106, 1999.
10) 清水一郎, 他:慢性関節リウマチの臼底突出に対して骨移植を併用した人工股関節置換術例の検討. 日人工関節会誌 30:293-294, 2000.
11) 清水一郎, 他:リウマチにおける髄内釘を用いた足関節固定術の成績. 関節の外科 17:1-4, 2001.
12) Stone KH, et al:A method of ankle stabilization. Clin Orthop 268:102-106, 1991.
13) 高倉義典:慢性関節リウマチ足の手術的療法. New Mook整外 1:248-256, 1997.
14) 辻本晴俊:慢性関節リウマチに対する関節鏡による膝関節鏡視下洗浄療法の効果. 臨リウマチ 12:53-56, 2000.
15) 上野貢生:RAにおける鏡視下膝関節洗浄術の効果. 日関外誌 20(1):55-58, 2001.
P.242 掲載の参考文献
1) Masi A T, et al:Articular patterns in the early course of rheumatoid arthritis. Am J Med 75:16-26, 1983.
2) Yamamoto S, et al:Can DMARDs prevent articular destruction in RA? J Orthopaedic Rheumatology 9:52-56, 1996.
3) Ochi T, et al:Natural course of joint destruction and fluctuation of serum Clq levels in patients with rheumatoid arthritis. Arthritis Rheum 31:37-43, 1998.
4) 山田昭夫, 他:慢性関節リウマチの生命予後に関する因子について. 平成7年度厚生省長期慢性疾患総合研究事業リウマチ調査研究総合研究報告書, p151-153. 国立相模原病院事務局, 神奈川, 1996.
5) Wolfe F W, et al:The mortality of rheumatoid arthritis. Arthritis Rheum 37:481-494, 1994.
6) 鈴木厚, 他:慢性関節リウマチ140例の死因に関する検討. リウマチ34:601-607, 1994.
7) 居村茂明, 他:慢性関節リウマチ患者の実態と下肢に人工関節置換を受けた患者QOLの経年変化. 平成7年度厚生省長期慢性疾患総合研究事業研究報告書, p147-157. 国立相模原病院事務局, 神奈川, 1996.
8) 大田寛:慢性関節リウマチ患者の死因と寿命. リウマチ病セミナーIII(七川歓次 監修), p85-94. 永井書店, 大阪, 1992.
9) 橋本明, 他:RA患者のQOL:AIMS2改訂 日本語版調査票を用いた多施設共同調査成績. I. 肢体不自由に関与する諸因子の解析. リウマチ 41:9-24, 2001.
10) 松岡剛正, 他:関節リウマチの早期重症化 (呼吸器合併症における) 指標. H18年度厚生労働科学研究費補助金免疫アレルギー疾患予防・治療研究事業研究報告抄録集. p335. 2008
12) 松田剛正:消化管アミロイドーシス. リウマチ科 21:446-450, 1999.
13) 豊島良太:慢性関節リウマチにおける骨粗鬆症. リウマチ 40:728-735, 2000.
14) 東 午郎, 他:RA骨粗鬆症の検討. 九州リウマチ18:58-63, 1999.
15) Hanyu T, et al:Structural mechanisms of bone loss in iliac biopsies:Comparison between rheumatoid arthritis and postmenopausal osteoporosis. Rheumatol Int 18:193-200, 1999.
16) 宗圓聰:リウマチに伴う骨粗鬆症の臨床像. リウマチ科 28:18-23, 2002.
P.248 掲載の参考文献
1) Kvien T K:Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22(2 Suppl 1):1-12, 2004.
2) 越智隆弘, 他 編:診断のマニュアルとEBM に基づく治療ガイドライン. 関節リウマチの診療マニュアル(改訂版). 財団法人日本リウマチ財団, 東京, 2004.
3) 平成16年度厚生労働科学研究免疫アレルギー予防治療等研究事業「関節リウマチの先端的治療に関する研究 (主任研究者 西岡久寿樹)」研究報告書, 2005.
4) 平成16年度厚生労働科学研究免疫アレルギー予防治療等研究事業「関節リウマチの疫学 患者の受療動態に関する研究 (主任研究者 吉田勝美) 」研究報告書, 2005.
5) Suka M, et al:Cost-effectiveness of Leflunomide in the treatment of rheumatoid arthritis in Japan:macro-level economic evaluation using disability-adjusted life years. Expert Rev Pharmacoeconomics Outcomes Res 4:617-622, 2004.
6) 須賀万智, 他:既存の統計資料を用いた推計によるマクロ的医療経済効果の評価:関節リウマチの新規治療薬導入. 厚生の指標 52:26-30, 2005.
7) Murray CJ, et al:The Global Burden of Disease:a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard, Harvard University Press, 1996.

第7章 治療ガイドライン

P.256 掲載の参考文献
1) Guidelines for the management of rheumatoid arthritis 2002 Uodate. Arthritis Rheum 46(2):328-3346, 2002.
2) 関節リウマチの診療マニュアル(改訂版) 診断のマニュアルとEBMに基づく治療ガイドライン (越智隆弘他 編). 日本リウマチ財団, 東京, 2004. (http://www.rheuma-net.or.jp/rheuma/rm400/library/guideline.htm)
3) 慢性関節リウマチの診察治療マニュアル (厚生省長期慢性疾患総合研究事業リウマチ班 編) 日本リウマチ財団, 東京, 1997. (http://www.rheuma-net.or.jp/rheuma/rm140/rm140-0.html.
4) Singh G:Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 105:31S-38S, 1998.
5) Frampton J E, et al:Celecoxib:areview of its use in the management of arthritis and acute pain. Drugs 67(16):2433-2472, 2007.
6) van Everdingen A A, et al:Low-dose prednisone therapy for patients with early active rheumatoid arthritis:clinical efficacy, disease-modifying properties, and side effects:a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136(1):1-12, 2002.
7) Wilske K R, et al:Remodeling the pyramid-a concept whose time has come. J Rheumatol 16(5):565-567, 1989.
9) Goekoop-Ruiterman Y P, et al:Comparison of treatment strategies in early rheumatoid arthritis:a randomized trial. Ann Intern Med 146(6):406-415, 2007.
10) Fries J F:Reevaluating the therapeutic approach to rheumatoid arthritis:the "saw-tooth" strategy. J Rheumatol Suppl 22:12-15, 1990.
11) Kitahara K, et al:Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol 19(3):238-245, 2007.
13) Moreland L W:Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol Suppl 57:7-15, 1999.
14) 関節リウマチ (RA) に対するTNF阻害療法施行ガイドライン(改訂版): http://www.ryumachi-jp.com/info/080201.html
P.268 掲載の参考文献
1) 厚生労働省研究班編:関節リウマチの診療マニュアル(改訂版) 診断のマニュアルとEBMに基づく治療ガイドライン. 財団法人日本リウマチ財団, 東京, 2004.
4) Koike R, et al:Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. (in press)
5) Maini R, et al:Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:a randomized phase III trial. Lancet 354:1932-1939, 1999.
9) Weinblatt M E, et al:Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum 48:35-45, 2003.
11) Keane J, et al:Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Eng J Med 345:1098-1104, 2001.
14) Mohan N, et al:Demyelination occurring during anti-tumor necrosis factorαtherapy for inflammatory arthritides. Arthritis Rheum 44:2862-2869, 2001.
15) Takeuchi T, et al:Post-marketing surveillance of the safety profile of infliximab in 5,000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. (in press)
16) ワイス株式会社, 武田薬品工業株式会社:適正使用情報 vol.4, 2006年6月.
18) Den Broeder AA, et al:Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor:a large retrospective study. J Rheumatol 34:689-695, 2007.
20) Baecklund E, et al:Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692-701, 2006.
21) Geborek P, et al:Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64:699-703, 2005.
24) Chakravarty E F, et al:Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 32:2130-2135, 2005.
25) Bongartz T, et al:Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 17:2275-2285, 2006.
26) Setoguchi S, et al:Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54:2757-2764, 2006.

第8章 トピックス

P.278 掲載の参考文献
1) Arnett F C, et al:The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324, 1988.
4) van der Helm-van Mil A H, et al:Aprediction rule for disease outcome in patients with recent-onset undifferentiated arthritis:how to guide individual treatment decisions. Arthritis Rheum 56:433-440, 2007.
5) Combe B, et al:EULAR recommendation fbr the management of early arthritis:report of a task force of the European Standing Committee fbr International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66:34-45, 2007.
6) Tamai M, et al:Early prediction of rheumatoid arthritis by serologic variables and magneric resonance imaging of the wrists and finger joints:Results from prospective Clinical examination. Ann Rheum Dis 65:134-135, 2006.
7) McQueen F M:Magnetic resonance image in early inflammatory artiritis:what is its role? Rheumatology 39:700-706, 2000.
9) Yamanaka H, et al:Serum matrix metallo-proteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis, Arthritis Rheum 43:852-858, 2000.
11) Tamai M, et al:Bone edema determined by magnetic resonance imaging reflectd Severe disease status in patients with early-stage rheumatoid arthritis. J Rheumatol 34:2154-2157, 2007.
12) van Dongen H, et al:Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis:adouble-blind, randomized, placebo-controlled trial. Arthritis Rheum 56:1424-1432, 2007.
P.285 掲載の参考文献
1) American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines:Guidelines for the management of rheumatoid arthritis:2002 update. Arthritis Rheum 46:328-346, 2002.
3) Yamanaka H, et al:Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol 17:28-32, 2007.
5) Maini R N, et al:Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50:1051-1065, 2004.
6) Quinn M A, et al:Very early treatment with infliximab in addition to methotrexate in early, poorprognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal:results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52:27-35, 2005.
7) Smolell J S, et al:Infliximab inhibits Radiographic Progression Regardless of Disease Activity at Baseline and Following Treatment in Patients with Early Active Rhematoid Arthritis. ACR. #466, 2006.
11) Goekoop-Ruiterman Y P, et al:Comparison of treatment strategies in early rheumatoid arthritis:arandomized trail. Ann Intern 146:406-415, 2007.
12) Guler-Yuksel M, et al:Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis. Ann Rheum Dis (in press)
P.293 掲載の参考文献
1) O'Dell J R:Treating rheumatoid arthritis early:awindow of opportunity? Arthritis Rheum 46:283-285, 2002.
4) Landewe R B, et al:COBRA combination therapy in patients with early rheumatoid arthritis:long-term structural benefits of a brief intervention. Arthritis Rheum 46:347-356, 2002.
5) Mottonen T, et al:Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46:894-898, 2002.
8) St Clair E W, et al:Combination of infliximab and methotrexate therapy for early rheumatoid arthritis:arandomized, controlled trial. Arthritis Rheum 50:3432-3443, 2004.
9) Quinn M A, et al:Very early treatment with infliximab in addition to methotrexate in early, poorprognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal:results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52:27-35, 2005.
10) Bathon J M, et al:Acomparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343:1586-1593, 2000.
12) Guidelines for the management of rheumatoid arthritis:2002 Update. Arthritis Rheum 46:328-346, 2002.
13) Scott D L:The diagnosis and prognosis of early arthritis:rationale for new prognostic criteria. Arthritis Rheum 46:286-290, 2002.
P.298 掲載の参考文献
7) Koike T, et al:Safety outcomes from a large Japanese post-marketing surveillance for etanercept Arthritis Rheum 56:S182, 2007.
8) Komano Y, et al:Predictors of Pneumocystis Pneumonia (PCP) in Patients with Rheumatoid Arthritis (RA) Under Infliximab (IFX) Therapy:AMulticenter Case-Control Sutdy. Arthritis Rheum 54:S516, 2006.
10) Marty F M, et al:(1->3) beta-D-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med 147:70-72, 2007.

最近チェックした商品履歴

Loading...